A Second Baby Has Been Born Via Uterus Transplant in the U.S.
A second woman in the U.S. born without a uterus has given birth to a baby, thanks to a uterus transplant. The birth took place at Baylor University Medical Center at Dallas, a part of Baylor Scott &White, which performed the first birth via uterus transplant late last year. The baby, born in February, is a girl. The hospital is not revealing the identity of the mother, but says the pregnancy and birth were uncomplicated. The birth is the second in the hospital’s ongoing uterus transplant clinical trial. The women in the trial have absolute uterine factor infertility (AUI), which means their uterus is nonfunctioning or nonexistent. Like the first woman to give birth as part of the trial, the woman who gave birth in February has a condition called Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome, which means she was born without a uterus and lived her life believing she would never be able to be pregnant or give birth. The woman was transplanted with a uterus from a living donor. Such procedures, while still experimental, could provide another option for families dealing with AUI, including women who have had their uterus removed for medical reasons like cancer. MORE: First U.S. Baby Born After a Uterus Transplant “Emotionally this was the same level of intensity [as the first birth],” says Dr. Giuliano Testa, the leader of the uterus transplant clinical trial at Baylor, and surgical chief of abdominal transplant for Baylor Annette C. and Harold C. S...
The thumbnail take on finasteride has been that it prevents prostate cancer but increases the risk for high-grade disease. A new study debunks the latter idea.Medscape Medical News
Smart technologies can sift through data to help the NHS spot diseases quicker, the PM is to say.
LONDON (Reuters) - Prime Minister Theresa May will call on Britain's health service, charities and artificial intelligence sector to work together to better identify patients with the early stages of cancer and stop thousands dying each year.
This article will discuss those efforts and results to date. PMID: 29766832 [PubMed - as supplied by publisher]
This study assessed the survival impact of combined surgery to the primary tumor and metastatic disease in the management of metastatic NSCLC. Stage IV NSCLC patients at presentation, diagnosed from 2004 to 2013 were identified from the SEER (Surveillance, Epidemiology, and End Results) database. Propensity-matched analysis was performed considering baseline characteristics (age, gender, race, histology, TN stage, and site of metastases). A total of 144,334 patients were identified. The median age group was 65-70 years, and 1139 patients (0.8% of the patients) have received surgical treatment to both the primary tumor...
In conclusion, NSUN2 is a potential independent prognostic marker and may be a potential therapeutic target in HNSCC. PMID: 29775108 [PubMed - in process]
Authors: Kocaba V, Damour O, Auxenfans C, Burillon C Abstract In France, endothelial dysfunction represents approximately one half of the indications for corneal transplants performed each year. However, the use of endothelial keratoplasty is limited by the technical difficulty of the procedure, a shortage of available grafts, and the potential for graft failure or rejection. These limitations are driving researchers to develop new, less invasive, and more effective therapies. Corneal endothelial cell therapy is being explored as a potential therapeutic measure, to avoid the uncertainty associated with grafting. Th...
The costs associated with a cancer diagnosis can add to a patient's stress, which can have a negative effect on outcome. Nurses can help by being prepared to discuss the financial aspects of care.Medscape Medical News
[The Conversation Africa] As cancer and other non-infectious diseases continue to rise all over the world it's become harder for scientists to find safe, effective treatments. In addition, bacteria are becoming more and more resistant to drugs and synthetic medicines have become harsher.
Abstract Hypoxia plays a crucial role in cancer progression, and it has great significance for monitoring hypoxic level in biosystems. Cancer stem cells (CSCs) represent a small population of tumour cells that regard as the key to seed tumours. The survival of CSCs depend on the tumour microenvironment, which is distinct region has the hypoxic property. Therefore, the detection of the hypoxic CSC niche plays a pivotal role in the destructing the 'soil' of CSCs, and eliminating CSCs population. Numerous one-photon excited fluorescent probes have been developed to indicate the hypoxic status in tumours through the d...
More News: Babies | Cancer | Cancer & Oncology | Cancer of the Uterus | Clinical Trials | Girls | Health | Hospitals | Infertility | Insurance | Insurers | Learning | Men | MRKH Syndrome | Ovarian Cancer | Ovaries | Pregnancy | Reproduction Medicine | Study | Sweden Health | Transplant Surgery | Transplants | Universities & Medical Training | USA Health | Women